- $194.24m
- -$14.48m
- $134.48m
Eye care company Alcon raises margin outlook, shares jump (updated)
RxSight, Inc. reports results for the quarter ended June 30 - Earnings Summary
RxSight Q2 adjusted loss beats estimates; withdraws 2026 guidance
Brief: Rxsight Inc Q2 Operating Expenses USD 39.7 Million
RxSight, Inc. expected to post a loss of 33 cents a share - Earnings Preview
Brief: Rxsight Announces Appointments Of Aziz Mottiwala As Chief Executive Officer And Ron Kurtz, M.D. As Chief Medical Officer
Swiss stocks - Factors to watch on July 7
Corrected: RxSight says Q2 results hit by more widespread competitive trialing
RxSight Q1 revenue beats estimates
Brief: Rxsight Q1 Revenue USD 30.9 Million Vs. IBES Estimate USD 29.7 Million
RxSight Q4 revenue falls 19% on lower LDD sales
Brief: Rxsight Q4 Gross Profit USD 25.3 Million
RxSight Q4 revenue rises 10%, beats analyst expectations
Brief: RxSight Says Mark Wilterding Appointed As CFO Effective Jan 11, 2026
Brief: RxSight, Inc. Announces Chief Financial Officer Transition
Medical device maker RxSight beats Q3 revenue estimates , narrows 2025 revenue forecast
Brief: Rxsight Q3 Revenue USD 30.3 Million Vs. IBES Estimate USD 25.3 Million
Rxsight Inc reports results for the quarter ended June 30 - Earnings Summary
Ophthalmic medical tech firm RxSight Q2 revenue falls